Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Interv Aging. 2010 Apr 26;5:119-21.

A need for evidence-based clinical practice guidelines for the use of heparins in the elderly.

Author information

1
Assistance Publique Hôpitaux de Paris, Laboratoire d'Hématologie, Hôpital Charles Foix, and Université Paris Descartes, INSERM U, Paris, France. isabelle.gouin@cfx.aphp.fr

Abstract

Low-molecular-weight heparins (LMWHs) have been widely studied in pivotal clinical trials or in several meta-analyses. However, the safety and optimal use of LMWHs in high-risk patients such as the very elderly remains uncertain since these patients are usually excluded from clinical trials. In terms of LMWHs in the elderly, the main concerns are renal failure and the risk of accumulation. A clinical approach consisting of a LMWH dose reduction in the elderly should be considered with great caution in terms of efficacy, since it has been tested neither in the treatment of VTE nor in VTE prophylaxis. If monitoring is considered in patients receiving therapeutic dose LMWHs, appropriate target ranges for peak anti-Xa activity levels should be used and so far, no anti-Xa activity-based guidelines have been issued. Moreover, no data support any laboratory monitoring in elderly patients treated with prophylactic dose LMWHs.

KEYWORDS:

elderly patients; evidence-based medicine; low-molecular-weight heparin; renal insufficiency

PMID:
20458349
PMCID:
PMC2861846
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Support Center